Skip to main navigation Skip to search Skip to main content

Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

  • Israel Lowy,

Press/Media

Period23 Oct 2023

Media coverage

1

Media coverage

  • TitleLibtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
    Media name/outletMarket News Publishing
    Country/TerritoryUnited States
    Date23/10/23
    PersonsIsrael Lowy,
View all 1
View less